

LumiRISK™

A multi-cancer panel provides a comprehensive coverage of 40 genes related to 11 cancers to assess an individual's risk of developing hereditary cancer. Knowing their risk of cancer early can enable patients to take better preventive action.

Cancer types covered:

Breast Ovarian Endometrial Prostate Colon Lung
Pancreatic Gastric Kidney Thyroid Melanoma

Recommended for:

Individuals who wish to be informed of their cancer risk especially those who have a family history of cancer.

Genes Evaluated

| | | | | | |
|--------------------------|--------------------------|------------------------------|-----------------------------|-------------------------|---------------|
| <i>APC</i> | <i>ATM</i> | <i>AXIN2</i> | <i>BAP1</i> | <i>BARD1</i> | <i>BMPR1A</i> |
| <i>BRCA1[^]</i> | <i>BRCA2[^]</i> | <i>BRIP1</i> | <i>CDH1</i> | <i>CDK4</i> | <i>CDKN2A</i> |
| <i>CEBPA</i> | <i>CHEK2</i> | <i>DICER1</i> | <i>EGFR^{T790M}</i> | <i>ERCC2</i> | <i>FANCA</i> |
| <i>FH</i> | <i>FLCN</i> | <i>HOXB13^{G84E}</i> | <i>MEN1</i> | <i>MLH1[^]</i> | <i>MRE11</i> |
| <i>MSH2[^]</i> | <i>MSH6</i> | <i>MUTYH</i> | <i>NBN</i> | <i>NF1</i> | <i>PALB2</i> |
| <i>PMS2</i> | <i>PTEN</i> | <i>RAD50</i> | <i>RAD51C</i> | <i>RAD51D</i> | <i>RET</i> |
| <i>SMAD4</i> | <i>STK11</i> | <i>TP53</i> | <i>VHL</i> | | |

LumiTHERA™

Analyzes 16 genes, including those in the Homologous Recombination Repair (HRR) pathway. The panel covers guideline-recommended genes to match actionable results with U.S. FDA-approved targeted therapies.

Cancer types covered:

Breast Ovarian Prostate Pancreas

Recommended for:

Patients who have breast, ovarian, prostate, or pancreatic cancer that may be inherited.

Genes Evaluated

| | | | | | |
|-------------------------|-------------------------|--------------------------|--------------------------|--------------|--------------|
| <i>ATM</i> | <i>BARD1</i> | <i>BRCA1[^]</i> | <i>BRCA2[^]</i> | <i>BRIP1</i> | <i>CHEK2</i> |
| <i>MLH1[^]</i> | <i>MSH2[^]</i> | <i>MSH6</i> | <i>MUTYH</i> | <i>PALB2</i> | <i>PMS2</i> |
| <i>PTEN</i> | <i>RAD51C</i> | <i>RAD51D</i> | <i>TP53</i> | | |

LumiFOCUS™

Cancer-specific panels examine genes associated with specific hereditary cancers.

Recommended for

Individuals who wish to be informed of their cancer risk especially those who have relatives diagnosed with the same type of cancer at a younger age.

LumiFOCUS™ Gynaecological

| | | | | | | | | |
|------------|---------------------------|---------------------------|--------------|-------------|---------------|--------------------------|--------------------------|-------------|
| <i>ATM</i> | <i>BRCA1</i> [^] | <i>BRCA2</i> [^] | <i>BRIP1</i> | <i>CDH1</i> | <i>CHEK2</i> | <i>MLH1</i> [^] | <i>MSH2</i> [^] | <i>MSH6</i> |
| <i>NBN</i> | <i>NF1</i> | <i>PALB2</i> | <i>PMS2</i> | <i>PTEN</i> | <i>RAD51C</i> | <i>RAD51D</i> | <i>STK11</i> | <i>TP53</i> |

LumiFOCUS™ Breast

| | | | | |
|-------------|---------------|---------------------------|---------------------------|-------------|
| <i>ATM</i> | <i>BARD1</i> | <i>BRCA1</i> [^] | <i>BRCA2</i> [^] | |
| <i>CDH1</i> | <i>CHEK2</i> | <i>NF1</i> | <i>PALB2</i> | |
| <i>PTEN</i> | <i>RAD51C</i> | <i>RAD51D</i> | <i>STK11</i> | <i>TP53</i> |

LumiFOCUS™ Colon

| | | | |
|--------------------------|--------------|---------------|--------------------------|
| <i>APC</i> | <i>AXIN2</i> | <i>BMPR1A</i> | <i>MLH1</i> [^] |
| <i>MSH2</i> [^] | <i>MSH6</i> | <i>MUTYH</i> | <i>PMS2</i> |
| <i>PTEN</i> | <i>SMAD4</i> | <i>STK11</i> | |

LumiFOCUS™ Gastric

| | | | |
|---------------|--------------|--------------------------|--------------------------|
| <i>BMPR1A</i> | <i>CDH1</i> | <i>MLH1</i> [^] | <i>MSH2</i> [^] |
| <i>MSH6</i> | <i>MUTYH</i> | <i>PMS2</i> | <i>SMAD4</i> |
| <i>STK11</i> | | | |

LumiFOCUS™ Kidney

| | | | |
|-------------|-------------|-------------|-------------|
| <i>BAP1</i> | <i>FH</i> | <i>FLCN</i> | <i>MET</i> |
| <i>PTEN</i> | <i>SDHA</i> | <i>SDHB</i> | <i>SDHC</i> |
| <i>SDHD</i> | <i>TSC1</i> | <i>TSC2</i> | <i>VHL</i> |

LumiFOCUS™ Pancreas

| | | | |
|--------------------------|---------------------------|---------------------------|---------------|
| <i>ATM</i> | <i>BRCA1</i> [^] | <i>BRCA2</i> [^] | <i>CDKN2A</i> |
| <i>MLH1</i> [^] | <i>MSH2</i> [^] | <i>MSH6</i> | <i>PALB2</i> |
| <i>PMS2</i> | <i>STK11</i> | <i>TP53</i> | |

LumiFOCUS™ Prostate

| | | | |
|--------------|-------------------------------|---------------------------|--------------------------|
| <i>ATM</i> | <i>BRCA1</i> [^] | <i>BRCA2</i> [^] | <i>CHEK2</i> |
| <i>FANCA</i> | <i>HOXB13</i> ^{G84E} | <i>MLH1</i> [^] | <i>MSH2</i> [^] |
| <i>MSH6</i> | <i>PALB2</i> | <i>PMS2</i> | <i>RAD51D</i> |

Technical Specifications of Lumi Series Tests

Technology

Next-generation sequencing analysis of entire coding sequences of the genes listed, including 10bp flanking intronic regions. Optional add-on for MLPA (Multiplex Ligation-dependent Probe Amplification) testing for Large Genomic Rearrangements (LGR) detection in *BRCA1*, *BRCA2*, *EPCAM*[#], *MLH1*, and *MSH2*.

Sensitivity

> 99%

Sample requirement

2 Streck tubes of blood (18ml in total)

Turnaround time

3 Weeks

[^]Optional add-on for MLPA (Multiplex Ligation-dependent Probe Amplification) testing for Large Genomic Rearrangements (LGR) detection.
[#]EPCAM Deletion testing only (for MSH2 silencing).

Distributed by Parkway Labs | Contact to order: 69330801/ 62485807 | sgadmin@parkwaypantai.com

Lucence Service Laboratory 211 Henderson Road #04-02, Henderson Industrial Park, Singapore 159552
Lucence Diagnostics Pte Ltd is licensed by the Ministry of Health (Singapore) as a Clinical Laboratory (Licence Number: 1710039/03/202) under the Healthcare Services Act 2020. GST Registered 201605840N. Refer to www.lucence.com/order-terms for Terms of Use. © 2022 Lucence Diagnostics Pte. Ltd. All Rights Reserved.

Information for non-US medical professionals only

M2006E-SG-03, February 2022